DOCSLIB.ORG

FDA-Approved Drug Library Mini (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FDA-Approved Drug Library Mini (96-Well) • Inhibitors • Agonists • Screening Libraries www.MedChemExpress.com FDA-Approved Drug Library Mini (96-well) Product Details: Catalog Number: HY-L022M Formulation: A collection of 1559 marketed drugs supplied as pre-dissolved DMSO solutions Container: 96 Well Microplate With Peelable Foil Seal Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: HY-L022M-1 1 2 3 4 5 6 7 8 9 10 11 12 Plerixafor Zoledronic a Empty Sisomicin Streptomycin (octahydrochl acid Paromomycin Netilmicin Neomycin Levoleucovori Peramivir Capreomycin Empty (sulfate) (sulfate) oride) (monohydrate (sulfate) (sulfate) (sulfate) n (Calcium) (trihydrate) (sulfate) 4- L-Glutamic b Empty Amikacin Stibogluconat Gluconate Histamine Mangafodipir Cromolyn (Aminomethyl acid Citicoline Tranexamic Empty (sulfate) e (sodium) (Calcium) (phosphate) (trisodium) (sodium) )benzoic acid monosodium acid Ozagrel Chloroquine Heparin Sugammadex Citicoline Ribostamycin c Empty sodium (diphosphate) Gadobutrol L-Ornithine (sodium salt) (sodium) Zanamivir sodium salt (sulfate) Glucosamine Empty d Empty L-Arginine Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty e Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty f Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty g Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty h Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Plate layout: HY-L022M-2 1 2 3 4 5 6 7 8 9 10 11 12 Etomidate Epirubicin Tetramisole a Empty Ibrutinib (hydrochlorid Tebipenem (hydrochlorid Raltitrexed Guanabenz Danofloxacin Ioversol Balofloxacin (hydrochlorid Empty e) pivoxil e) (Acetate) (mesylate) e) Bephenium b Empty Metaxalone Nitrofurazone Rocuronium Ademetionine Micafungin Gemifloxacin Cefuroxime (hydroxynaph Cefoselis Ifenprodil Empty (Bromide) (sodium) (mesylate) (sodium) thoate) (sulfate) (tartrate) Amorolfine Clomipramine c Empty Levosimenda (hydrochlorid Dehydrocholi (hydrochlorid Mefenamic Tofacitinib Biapenem Lacidipine Telbivudine Nicotinamide Empty n e) c acid e) acid (citrate) Cloxacillin Bromphenira d Empty Toremifene Gluconate Sulfaguanidin (sodium mine Imatinib Amifostine Rosiglitazone Ozenoxacin Tenofovir Empty (Citrate) (sodium) e monohydrate) (maleate) (Mesylate) (maleate) alafenamide Imidapril 5- Benidipine e Empty (hydrochlorid Epinastine Aminosalicylic (hydrochlorid Vitamin B12 Empty Empty Empty Empty Empty Empty e) Acid e) f Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty g Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty h Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Plate layout: HY-L022M-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] • Inhibitors • Agonists • Screening Libraries www.MedChemExpress.com Reserpine a Empty Lumefantrine Acetylcystein Piracetam Brimonidine Succinylsulfat Bifonazole Azelnidipine (hydrochlorid Ursodiol Vigabatrin Empty e (tartrate) hiazole e) 3,3',5-Triiodo- Octreotide b Empty L-thyronine Rofecoxib Felbamate Trelagliptin Pralatrexate (acetate) Gadodiamide Rutin Lamotrigine Clevidipine Empty Dexmedetomi Empty Pyrantel Allantoin Goserelin Rotundine Brexpiprazole Caspofungin Salmeterol Bromocriptine dine Dimethyl Empty c (pamoate) (acetate) (Acetate) (xinafoate) (mesylate) (hydrochlorid fumarate Cetylpyridiniu Asenapine d Empty Novobiocin Atracurium Sulfaphenazo m (chloride Nadifloxacin Propylthioura (hydrochlorid Rifaximin Afatinib Clofazimine Empty (Sodium) (besylate) le monohydrate) cil e) (dimaleate) Efonidipine Sapropterin e Empty (hydrochlorid (dihydrochlori Rufinamide Cilastatin Chlorpropami Methimazole Pancuronium Oxantel Mosapride Alverine Empty e de) de (dibromide) (pamoate) (citrate) (citrate) Oxacillin Trihexyphenid Amitriptyline f Empty Dutasteride Penciclovir Dimetridazole (sodium Mycophenolat Dexamethaso yl Rupatadine Azithromycin (hydrochlorid Empty monohydrate) e Mofetil ne (acetate) (hydrochlorid (Fumarate) e) Tenofovir Aliskiren g Empty alafenamide Anethole (hemifumarat Capecitabine Pentostatin Valsartan Delamanid Pimecrolimus Ribociclib Bemegride Empty hemifumarate (trithione) e) succinate L-(-)-α- Methacycline Lercanidipine h Empty Gamithromyci Methyldopa Trimethadion Benzamil (hydrochlorid 1-Docosanol Etravirine Piperacillin (hydrochlorid Methotrexate Empty n (hydrate) e hydrochloride e) (sodium) e) Plate layout: HY-L022M-4 1 2 3 4 5 6 7 8 9 10 11 12 Phenoxybenz Carbamoylch Pitolisant a Empty N/A Dapagliflozin amine oline Lecithin Topiramate Bedaquiline Gestodene Niclosamide (hydrochlorid Empty (hydrochlorid (chloride) (fumarate) e) Solifenacin Triflupromazi Hydroxyfasud sn-Glycero-3- b Empty (hydrochlorid Nitrendipine Ornipressin ne Natamycin il Auranofin Primidone phosphocholi Oxeladin Empty e) (hydrochlorid (hydrochlorid ne (citrate) Clemizole Azaphen c Empty Olsalazine (hydrochlorid Primaquine Scopolamine (dihydrochlori Ropivacaine Ledipasvir Chlorthalidon Bisoctrizole Verteporfin Empty (Disodium) e) (Diphosphate) butylbromide de hydrochloride (acetone) e Nitroprusside Guanidine d Empty (disodium Cephalothin Warfarin Selumetinib Fosinopril Avobenzone (hydrochlorid Dirithromycin Miriplatin Deferoxamine Empty dihydrate) (sodium) (sodium) e) (mesylate) Trimetazidine Irinotecan Bromhexine e Empty Tolazamide Tafluprost Diquafosol (dihydrochlori Saquinavir Nintedanib Monensin (hydrochlorid Omeprazole (hydrochlorid Empty (tetrasodium) de) sodium salt e) e) Azelastine Buflomedil f Empty Perindopril (hydrochlorid Miridesap Halcinonide Hydroxychlor (hydrochlorid Spiramycin Levosulpiride Dequalinium (+)- Empty (erbumine) e) oquine sulfate e) (Chloride) Ketoconazole Mepivacaine Nafcillin Trametinib Betaxolol Dihydroergota g Empty (hydrochlorid Ixazomib Tafamidis (sodium (DMSO (hydrochlorid mine Tenofovir Plerixafor Dabigatran Empty e) monohydrate) solvate) e) (mesylate) (hydrate) etexilate Sertraline Quinapril Fasudil h Empty Oxybutynin Desonide (hydrochlorid (hydrochlorid Pamidronic Methoxsalen Almitrine Carfilzomib (Hydrochlorid Cloperastine Empty e) e) acid mesylate e) fendizoate Plate layout: HY-L022M-5 1 2 3 4 5 6 7 8 9 10 11 12 Pazopanib Pivmecillinam Tenofovir Proparacaine a Empty Lodoxamide (Hydrochlorid (hydrochlorid Fosfomycin alafenamide Venetoclax (Hydrochlorid Malotilate Lifitegrast Cidofovir Empty e) e) (calcium) fumarate e) Sotalol Avibactam Olprinone Citric acid b Empty (hydrochlorid Chlorocresol Zaltoprofen Ceftazidime Erythromycin Dimemorfan (sodium Prucalopride (Hydrochlorid (trilithium salt Empty e) (phosphate) hydrate) e) tetrahydrate) Cyclobenzapr L-Arginine Pamidronate Dantrolene c Empty ine Edrophonium (hydrochlorid (disodium Tiratricol (sodium Sorafenib Danazol Oxytetracyclin Imiquimod Empty (hydrochlorid (chloride) e) pentahydrate) hemiheptahy e Spectinomyci Empty Mestranol n Colchicine Kanamycin Sildenafil Paclitaxel Ruxolitinib Estriol Simeprevir Nedaplatin Empty d (dihydrochlori (sulfate) (citrate) 6- e Empty Faropenem Methylthioura Acetohydroxa Osimertinib Selexipag Risedronate Protoporphyri Firocoxib Guacetisal Aminocaproic Empty sodium cil mic acid mesylate (sodium) n IX acid Deoxycholic Lomefloxacin Cefepime f Empty Bestatin Sulfasalazine acid sodium (hydrochlorid Busulfan Piromidic acid Nelfinavir Avibactam Atazanavir (Dihydrochlori Empty salt e) (Mesylate) (sodium) (sulfate) de Fingolimod Alendronate Alprenolol Ibandronate g Empty (hydrochlorid Benzbromaro Alibendol (sodium Nimodipine Pazopanib Flufenamic (hydrochlorid Rebamipide (Sodium Empty e) ne hydrate) acid e) Monohydrate) Levobupivaca Amiodarone Vancomycin Besifloxacin Mexiletine h Empty ine α-Lipoic Acid (hydrochlorid Nitisinone (hydrochlorid (Hydrochlorid (hydrochlorid Pasiniazid Galanthamine Fondaparinux Empty (hydrochlorid e) e) e) e) (sodium) Plate layout: HY-L022M-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] • Inhibitors • Agonists • Screening Libraries www.MedChemExpress.com 1 2 3 4 5 6 7 8 9 10 11 12 Daunorubicin Lomerizine 3,3',5-Triiodo- a Empty Abacavir Parecoxib Vinblastine Cefditoren Doxazosin Selamectin Candesartan (Hydrochlorid dihydrochlorid L-thyronine Empty (sulfate) (sulfate) (Pivoxil) (mesylate) (Cilexetil) e) e (sodium) 4- Idarubicin Sodium Tosufloxacin b Empty Aminopyridin Brivudine (hydrochlorid Itraconazole Fulvestrant Fusidic acid Etoposide Ginsenoside tauroglycocho (tosylate Empty e e) (sodium salt) Rg3 late hydrate) Fexofenadine Conivaptan Cobimetinib Moexipril c Empty Eltrombopag Proglumide Dronedarone Sulbutiamine Gadodiamide (hydrochlorid (hydrochlorid (hemifumarat (hydrochlorid Telotristat Empty (Olamine) (hydrate) e) e) e) e) ethyl Nilotinib Teneligliptin d Empty (monohydroc Ombitasvir LCZ696 Penfluridol (hydrobromid Bepotastine Pentamidine Telithromycin Teniposide Hydroxyurea Empty hloride e) (Beslilate) (isethionate) Berberine e Empty Netupitant Velpatasvir Entrectinib Indacaterol Darunavir Telaprevir Lomitapide (chloride Iopanoic acid Mebhydrolin Empty (maleate) (Ethanolate) hydrate) (napadisylate) Tenofovir Dabigatran f Empty Ponatinib (Disoproxil Nintedanib Dienogest Metoprolol Rifabutin Montelukast Posaconazol Lopinavir etexilate Empty Fumarate) esylate (Succinate) (sodium) e (mesylate) Sivelestat g Empty Aclidinium Roxithromyci Avanafil Alectinib Indinavir Ceritinib Ciclesonide Ouabain (sodium Bazedoxifene Empty (Bromide) n Hydrochloride (sulfate) (Octahydrate) tetrahydrate) (acetate)
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Screening of a Composite Library of Clinically Used Drugs and Well
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Jos Journal 2
    POST-OPERATIVE AUDIT OF G6PD-DEFICIENT MALE CHILDREN WITH OBSTRUCTIVE ADENOTONSILLAR ENLARGEMENT AT UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA. John EN1, Totyen EL1, Jacob N2, Nwaorgu OGB1 1 .Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria 2. Department of paediatrics, University College Hospital, Ibadan, Nigeria All correspondences and request for reprint to Dr John EN, Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria Email: [email protected] Telephone: +2348036240109 Abstract Background: G6PD deficiency ranks among the commonest hereditary enzyme deficiency worldwide and notable as a predisposing condition to haemolyticcrises. The fear of possible untoward effects is often expressed by parents of G6PD deficient male children scheduled for surgery after obtaining an informed and understood consent. The parental perception of obstructive adenotonsillar enlargement in this condition was also appraised. Methods: A retrospective chart review of all G6PD deficient male children between ages 1 to 7years who had adenotonsillectomy over a 3year period at University college Hospital, Ibadan, Nigeria. Results: The patients comprised of 22 G6PD deficient male children diagnosed shortly after birth upon development of neonatal jaundice. Fifteen(68.2%) and 6(27.3%) of the patients subsequently developed episodes of drug- induced haemolysis and non-haemolytic drug reactions prior to undergoing adenotonsillectomy by the otolaryngologists. None of the patients was observed to develop haemolytic crises up to 2weeks post-adenotonsillectomy. From the parental perception and responses in the follow-up period,all 22(100%) patient had resolution of noisy breathing, 20(91%) had improvement of snoring and apnoeic spells. Only 15 (68%) were reported to stop mouth-breathing.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Systematic Review of the Effect of Intravenous Lipid Emulsion Therapy for Non-Local Anesthetics Toxicity
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity Michael Levine, Robert S. Hoffman, Valéry Lavergne, Christine M. Stork, Andis Graudins, Ryan Chuang, Samuel J. Stellpflug, Martin Morris, Andrea Miller-Nesbitt, Sophie Gosselin & for the Lipid Emulsion Workgroup* To cite this article: Michael Levine, Robert S. Hoffman, Valéry Lavergne, Christine M. Stork, Andis Graudins, Ryan Chuang, Samuel J. Stellpflug, Martin Morris, Andrea Miller-Nesbitt, Sophie Gosselin & for the Lipid Emulsion Workgroup* (2016) Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity, Clinical Toxicology, 54:3, 194-221, DOI: 10.3109/15563650.2015.1126286 To link to this article: http://dx.doi.org/10.3109/15563650.2015.1126286 Published online: 06 Feb 2016. Submit your article to this journal Article views: 692 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [UPSTATE Medical University Health Sciences Library] Date: 03 August 2016, At: 08:19 CLINICAL TOXICOLOGY, 2016 VOL. 54, NO. 3, 194–221 http://dx.doi.org/10.3109/15563650.2015.1126286 REVIEW Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetics toxicity Michael Levinea, Robert S. Hoffmanb, Vale´ry Lavergnec, Christine M. Storkd, Andis Graudinse, Ryan Chuangf, Samuel J. Stellpflugg, Martin Morrish, Andrea Miller-Nesbitth, Sophie Gosselini and for the Lipid Emulsion Workgroup* aDepartment of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, CA, USA; bDivision of Medical Toxicology, Ronald O.
    [Show full text]